Anti-Cancer MAbS Global Market Report 2024

The anti-cancer mabs market size has grown rapidly in recent years. It will grow from $59.98 billion in 2023 to $66.1 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The growth observed during the historical period in the field of anticancer monoclonal antibodies can be attributed to several factors. These include the increasing incidence rates of cancer, a growing understanding of cancer biology that has paved the way for targeted therapies, the rise in personalized medicine approaches tailoring treatments to individual patients, increased investment in research and development for cancer treatments, and a parallel increase in patient awareness and demand for advanced and effective cancer therapies. These factors collectively contributed to the development and adoption of anticancer monoclonal antibodies during the historic period.

The anti-cancer mabs market size is expected to see strong growth in the next few years. It will grow to $95.99 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. The anticipated growth in the forecast period in the field of anticancer monoclonal antibodies can be attributed to several factors. These include advancements in immunotherapy, the increasing adoption of combination therapies for more effective cancer treatment, the emergence of next-generation monoclonal antibodies, global efforts to address the burden of cancer, and the expansion of patient access programs to ensure broader availability of these therapies. Key trends expected in the forecast period encompass innovations in drug delivery technologies, the integration of artificial intelligence in drug discovery processes, collaborative initiatives and partnerships within the pharmaceutical industry, advancements in biotechnology, and the ongoing development of CAR-T cell therapies for cancer treatment. These trends collectively contribute to the continued evolution and expansion of the anticancer monoclonal antibody sector.

The increasing incidence of cancer worldwide is expected to drive the growth of the anticancer monoclonal antibodies (mAbs) market. Cancer is a chronic disease that affects millions of individuals globally. Anticancer mAbs are designed to target specific proteins found on cancer cells, using genetically engineered versions of the immune system's antibodies to combat cancerous cells. With the rising prevalence of cancer, there is a growing demand for more effective therapies such as anticancer mAbs. For instance, according to a January 2022 report from PubMed, an estimated 1.9 million new cancer cases are anticipated globally, with 609,360 cancer-related deaths expected in the United States. Consequently, the increasing prevalence of cancer is a significant driver for the growth of the anticancer mAbs market.

The proliferation of clinical trials is anticipated to further fuel the expansion of the anti-cancer mAbs market. Clinical trials play a vital role in advancing and refining anti-cancer monoclonal antibodies by evaluating their safety, efficacy, and potential mechanisms of action. They offer valuable insights into health-related biomedical or behavioral outcomes and are pivotal in the development and enhancement of these therapies. For instance, according to the World Health Organization's February 2023 report, the number of global clinical trials increased by 20%, reaching 744,100 trials in 2022 from 616,765 in 2020. This growth in clinical trials is a key factor driving the expansion of the anti-cancer mAbs market.

Product innovation is a prominent trend within the anticancer mAbs market, with major companies introducing more targeted and effective cancer treatments. For example, in May 2022, Roche Holding AG, a Switzerland-based pharmaceutical company, launched PHESGO, a unique combination treatment for HER2-positive early breast cancer. PHESGO consists of two monoclonal antibodies, pertuzumab and trastuzumab, combined with the enzyme hyaluronidase. This subcutaneous injection, leveraging hyaluronidase, enhances mAbs absorption, allowing for subcutaneous administration rather than intravenous, offering patients a more convenient treatment option. Such innovative approaches demonstrate a commitment to developing advanced and patient-friendly therapies within the anticancer mAbs market.

Major players in the anti-cancer monoclonal antibodies (mAbs) market are strategically focusing on innovative strategies, such as conducting clinical trials, to establish a competitive advantage in the industry. Clinical trials are pivotal research studies that assess the safety and efficacy of novel treatments, medications, or devices in human subjects. For instance, in April 2023, Y-mAbs Therapeutics Inc., a prominent clinical biopharmaceutical company based in the United States, initiated a Phase I Trial for GD2-Targeted Radioimmunotherapy. This trial aims to evaluate the safety and effectiveness of GD2-SADA, a pre-targeted radioimmunotherapy (RIT), in treating specific GD2-positive solid tumors such as small cell lung cancer, sarcoma, and malignant melanoma. GD2-SADA follows a distinctive two-step procedure to administer radiation to tumor cells. Initially, the SADA protein attaches to GD2 proteins present on the surface of various solid tumors. Subsequently, the radioactive ligand 177Lu-DOTA is introduced, binding to the SADA protein and delivering radiation specifically to the tumor cells. This two-step approach is devised to limit radiation exposure to healthy tissues.

In May 2021, Exelixis Inc., a US-based company specializing in genomics-based drug discovery, completed the acquisition of GamaMabs Pharma SA for $5 million. This acquisition was undertaken to integrate GamaMabs’ AMHR2 antibody technology into Exelixis Inc.'s assets, thereby expanding its current drug product portfolio with GamaMabs' offerings and associated manufacturing cell lines. GamaMabs Pharma SA, based in France, is a biotechnology company dedicated to the development of innovative monoclonal antibodies specifically designed for treating solid tumors.

Major companies operating in the anti-cancer mabs market report are Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Merck & Co. Inc., Spectrum Pharmaceuticals Inc., AstraZeneca plc., Pfizer Inc., Gilead Sciences Inc., Bayer HealthCare, ImmunoGen Inc., Genentech Inc., AbbVie Inc., Takeda Pharmaceuticals, Seattle Genetics, Regeneron Pharmaceuticals, Celgene, Ipsen, Daiichi Sankyo, Kite Pharma, ADC Therapeutics, MacroGenics Inc., BioXcel Therapeutics, Zymeworks Inc., Exelixis Inc., Blueprint Medicines, Erytech Pharma, Oncopeptides AB.

North America was the largest region in the anti-cancer MAbS market in 2023. Asia Pacific is expected to be the fastest-growing region in the anti-cancer MAbS market during the forecast period. The regions covered in the anti-cancer mabs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-cancer mabs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of anti-cancer mAbs include murine antibodies, chimeric antibodies, humanized antibodies, and others. Murine antibodies are a specific category of monoclonal antibodies that are laboratory-made copies of a single antibody. These antibodies are produced by a single B cell and are derived from mice or rats. They are engineered to bind to a specific antigen. Anticancer mAbs find applications in various cancer types, including blood cancer, breast cancer, lung cancer, melanoma, colorectal cancer, liver cancer, among others. These antibodies are used in settings such as hospitals, research institutes, and other medical facilities.

The anti-cancer MABs market research report is one of a series of new reports that provides anti-cancer MABs market statistics, including anti-cancer MABs industry global market size, regional shares, competitors with an anti-cancer MABs market share, detailed anti-cancer MABs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-cancer MABs industry. This anti-cancer MABs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.